Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice

Cellular and Molecular Immunology

Volumn 5, Issue 3, 2008, Pages 189-196

  Tang, Feng ^a   Zhao, Luting ^a   Jiang, Yan ^a   Ba, Denian ^a   Cui, Lianxian ^a   He, Wei ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

LA795; metastasis; recurrence; RhIL 15; transplantable experimental tumor model

Indexed keywords

INTERLEUKIN 15; RECOMBINANT PROTEIN;

ADENOCARCINOMA; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; HUMAN; IMMUNOLOGY; LIVER TUMOR; LUNG TUMOR; MALE; METABOLISM; METASTASIS; MOUSE; MOUSE STRAIN; RANDOMIZATION; TUMOR CELL LINE; TUMOR RECURRENCE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-15; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED STRAINS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; RANDOM ALLOCATION; RECOMBINANT PROTEINS;

EID: 51049088214     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2008.23     Document Type: Article

References (33)

1. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264:965-968. (Pubitemid 24196167)
2. Waldmann TA, Tagaya Y. The multifaced regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999;17:19-49. (Pubitemid 29241118)
3. Bamford RN, Grant AJ, Burton JD, et al. The interleukin-2 receptor-β chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994;91:4940-4944.
4. Nishimura H, Hiromatsu K, Kobayashi N, et al. IL-15 is a novel growth factor for murine γβ T cells induced by Salmonella infection. J Immunol. 1996;156:663-669. (Pubitemid 26029620)
5. Carson WE, Giri J G, Lindemann MJ, et al. Interleukin (IL)-15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395-1403. (Pubitemid 24289613)
6. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol. 1995;154:483-490.
7. + Tc1 responses in vivo. Eur J Immunol. 2004;34:66-73. (Pubitemid 38111521)
8. Girard D, Paquet ME, Paquin R, Beaulieu AD. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: mntitumor effects of human IL-15 gene modified lung cancer
9. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol. 1998;161:6977-6984. (Pubitemid 28562246)
10. Lasek W, Basak G, Switaj T, et al. Complete tumor regressions induced by vaccination with IL-12 gene-transduced tumor cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother. 2004;53:363-372. (Pubitemid 38392314)
11. Sabbagh L, Snell LM, Watts TH. TNF family ligands define niches for T cell memory. Trends Immunol. 2007;28:333-339. (Pubitemid 47077923)
12. Xia H, Luo LM, Wen JX, Tong WC. Inhibitory effects of recombinant human endostatin on growth and metastasis of lung adenocarcinoma LA795 in mice. Ai Zheng. 2002;21:1197-1202.
13. Zhang ZW. Establishment and study of biologic properties of a mouse lung adenocarcinoma cell line (LA795). Zhongguo Zhong Liu Za Zhi. 1985;7:83-85.
14. McCutcheon IE, Baranco RA, Katz DA, Saris SC. Adoptive immunotherapy of intracerebral metastases in mice. J Neurosurg. 1990;72:102-109. (Pubitemid 20027306)
15. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966;36:641-645.
16. Lasek W, Golab J, Maslinski W, Switaj T, et al. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. Eur Cytokine Netw. 1999;10:345-356. (Pubitemid 29415387)
17. Yoshida Y, Tasaki K, Kimurai M, et al. Antitumor effect of human pancreatic cancer cells transduced with cytokine genes which activate Th1 helper T cells. Anticancer Res. 1998;18:333-335. (Pubitemid 28174728)
18. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998;92:252-258. (Pubitemid 28303200)
19. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595-601. (Pubitemid 44134092)
20. Cao S, Troutt AB, Rustum YM. Interleukin-15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res. 1998;58:1695-1699. (Pubitemid 28215095)
21. Lewko WM, Smith TL, Bowman DJ, Good RW, Oldham RK. Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother. 1995;10:13-20.
22. Mingari MC, Vitale C, Cantoni C, et al. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Eur J Immunol. 1997;27:1374-1380. (Pubitemid 27254827)
23. Sheng YQ, Cui LX, He W, Xue L, Ba DN. Antitumor effects of human IL-15 gene modified lung cancer cell line. Chinese Journal of Cancer Research. 1997;9:240-244.
24. Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the band γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13:2822-2830. (Pubitemid 24191692)
25. + T cells. Proc Natl Acad Sci U S A. 2004;101:1969-1974. (Pubitemid 38228999)
26. Ye W, Young JD, Liu CC. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell Immunol. 1996;174:54-62. (Pubitemid 26414158)
27. Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY. Interleukin-15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res. 1995;55:4988-4994.
28. Takeuchi E, Yanagawa H, Yano S, Haku T, Sone S. Induction by interleukin-15 of human killer cell activity against lung cancer cell lines and its regulatory mechanisms. Jpn J Cancer Res. 1996;87:1251-1258. (Pubitemid 27042368)
29. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med. 1997;3:189-195. (Pubitemid 27064704)
30. Korholz D, Banning U, Bonig H, et al. The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses. Blood. 1997;90:4513-4521. (Pubitemid 27508457)
31. Di Carlo E, Comes A, Basso S, et al. The combined action of IL-15 and IL-12 gene transfer can induce tumour cell rejection without T and NK cell involvement. J Immunol. 2000;165:3111-3118.
32. Comes A, Di Carlo E, Musiani P, et al. IFN-γ-independent synergistic effects of IL-12 and IL-15 induce anti-tumour immune responses in syngeneic mice. Eur J Immunol. 2002;32:1914-1923. (Pubitemid 34814547)
33. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med. 2001;250:462-475. (Pubitemid 34013510)